Top

Published in:

01-02-2007 | Original paper

Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders

Authors: Ahmed M. Abu El-Asrar, Philippe E. Van den Steen, Saleh A. Al-Amro, Luc Missotten, Ghislain Opdenakker, Karel Geboes

Published in: International Ophthalmology | Issue 1/2007

Abstract

Purpose

To investigate the expression of connective tissue growth factor (CTGF) in the retina of human subjects with diabetes mellitus, and CTGF, CD105, and gelatinase B in proliferative diabetic retinopathy (PDR) and proliferative vitreoretinopathy (PVR) epiretinal membranes.

Methods

Twelve donor eyes from six subjects with diabetes mellitus, 10 eyes from five nondiabetic subjects, 14 PDR membranes, and five PVR membranes were studied by immunohistochemical techniques. In situ zymography was used to examine gelatinolytic activity in four PDR membranes.

Results

In nondiabetic retinas, there was no immunoreactivity for CTGF. Diabetic retinas showed immunoreactivity for CTGF in ganglion cells and microglia. Vascular endothelial cells in PDR membranes expressed CTGF, CD105, and gelatinase B in 10 (71.4%), 11 (78.6%), and 5 (35.7%) membranes, respectively. Myofibroblasts in PDR membranes expressed CTGF, and gelatinase B in 14 (100%), and 6 (42.9%) membranes, respectively. There was a significant correlation between the number of blood vessels expressing the panendothelial marker CD34 and the number of blood vessels expressing CTGF (r = 0.7884; P = 0.0008), and CD105 (r = 0.6901; P = 0.0063), and the number of myofibroblasts expressing CTGF (r = 0.5922; P = 0.0257). There was a significant correlation between the number of myofibroblasts expressing α-smooth muscle actin and the number of myofibroblaasts expressing CTGF (r = 0.8393; P = 0.0002). In situ zymography showed the presence of gelatinolytic activity in vascular endothelial cells in PDR membranes. Myofibroblasts in PVR membranes expressed CTGF, and gelatinase B.

Conclusions

These results suggest a possible role of CTGF, CD105, and gelatinase B in the pathogenesis of proliferative vitreoretinal disorders.

Blom IE, Goldschmeding R, Leask A (2002) Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol 21:473–482PubMedCrossRef

Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim H-S, Hwa V et al (2002) Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143:1260–1269PubMedCrossRef

Wang JF, Olson ME, Ball DK, Brigstock DR, Hart DA (2003) Recombinant connective tissue growth factor modulates porcine skin fibroblast gene expression. Wound Rep Reg 11:220–229CrossRef

Shimo T, Nakanishi T, Nishida T, Asano M, Kanyama M, Kuboki T et al (1999) Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo. J Biochem 126:137–145PubMed

Duff SE, Li C, Garland JM, Kumar S (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J 17:984–992PubMedCrossRef

Nguyen M, Arkell J, Jackson CJ (2001) Human endothelial gelatinase and angiogenesis. Int J Biochem Cell Biol 33:960–970PubMedCrossRef

Matrisian L (1990) Matrix metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121–125PubMedCrossRef

Paemen L, Martens E, Masure S, Opdenakker G (1995) Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity. Eur J Biochem 234:759–765PubMedCrossRef

Pagenstecher A, Stalder AK, Kincaid CL, Volk B, Campbell IL (2000) Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am J Pathol 157:197–210PubMed

10.

Oh LY, Larsen PH, Krekoski CA, Edwards DR, Donovan F, Werb Z et al (1999) Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes. J Neurosci 19:8464–8475PubMed

11.

Miller JW, Adamis AP, Aiello P (1997) Vascular endothelial growth factor in ocular neovascularization and proliferative retinopathy. Diabetes Metab Rev 13:37–50PubMedCrossRef

12.

Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J et al (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25–38PubMedCrossRef

13.

Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM et al (2002) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143:4907–4915PubMedCrossRef

14.

Zhou G, Li C, Cai L (2004) Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor (-independent pathway. Am J Pathol 165:2033–2043PubMed

15.

Ito Y, Aten J, Bende RJ, Oemar BS, Rabelink TJ, Weening JJ et al (1998) Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 53:853–861PubMedCrossRef

16.

Tikellis C, Cooper ME, Twigg SM, Burns WC, Tolcos M (2004) Connective tissue growth factor is up-regulated in the diabetic retina: amelioration by angiotensin-converting enzyme inhibition. Endocrinology 145:860–866PubMedCrossRef

17.

Kuiper EJ, Witmer AN, Klaassen I, Oliver N, Goldschmeding R, Schlingemann RO (2004) Differential expression of connective tissue growth factor in microglia and pericytes in the human diabetic retina. Br J Ophthalmol 88:1082–1087PubMedCrossRef

18.

Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M et al (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106:729–733PubMedCrossRef

19.

Rachfal AW, Brigstock DR (2003) Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 26:1–9PubMedCrossRef

20.

Meyer P, Wunderlich K, Klain HL, Prünte C, Flammer J (2002) Human connective tissue growth factor mRNA expression of epiretinal and subretinal fibrovascular membranes: a report of three cases. Ophthalmologica 21:284–291CrossRef

21.

Hinton DR, He S, Jin ML, Barron E, Ryan SJ (2002) Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye 16:422–428PubMedCrossRef

22.

He S, Jin ML, Worpel V, Hinton DR (2003) A role of connective tissue growth factor in the pathogenesis of choroidal neovascularization. Arch Ophthalmol 121:1283–1288PubMedCrossRef

23.

Hinton DR, Spee C, He S, Wetz S, Usinger W, LaBree L et al (2004) Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care 27:758–764PubMedCrossRef

24.

Kuiper EJ, de Smet MD, van Meurs JC, Tan HS, Tanck MWT, Oliver N et al (2006) Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol 124:1457–1462PubMedCrossRef

25.

Park SK, Kim J, Seomun Y, Choi J, Kim DH, Han IO et al (2001) Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 284:966–971PubMedCrossRef

26.

Kondo S, Kubota S, Shimo T, Nishida T, Yosimichi G, Eguchi T et al (2002) Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases. Carcinogenesis 23:769–776PubMedCrossRef

27.

Suzuma K, Naruse K, Suzuma I, Takahara N, Ueki K, Aiello LP et al (2000) Vascular endothelial growth factor induces expression of connective tissue growth factor via KDR, Fit1, and phosphatidylinositol 3-kinase-Akt-dependent pathways in retinal vascular cells. J Biol Chem 275:40725–40731PubMedCrossRef

28.

Torsney E, Charton R, Parums D, Collis M, Arthur HM (2002) Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 51:464–470PubMedCrossRef

29.

Dales JP, Garcia S, Bonnier P, Duffaud F, Andrac-Meyer L, Ramuz O et al (2003) CD105 expression is a marker of high metastatic risk and poor outcome in breast carcinomas. Correlation between immunohistochemical analysis and long-term follow-up in a series of 929 patients. Am J Clin Pathol 119:374–380PubMedCrossRef

30.

Saad RS, Liu YL, Nathan G, Gelebrezze J, Medich D, Silverman JF (2004) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 17:197–203PubMedCrossRef

31.

Gillard JA, Reed MW, Buttle D, Cross SS, Brown NJ (2004) Matrix metalloproteinase activity and immunohistochemical profile of matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 during human dermal wound healing. Wound Repair Regen 12:295–304PubMedCrossRef

32.

Ramos C, Montaño M, Garcia-Alvarez J, Ruiz V, Uhal BD, Selman M et al (2001) Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am J Respir Cell Mol Biol 24:591–598PubMed

33.

Majka S, McGuire PG, Das A (2002) Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci 43:260–266PubMed

34.

Behzadian MA, Wang X-L, Windsor LJ, Ghaly N, Caldwell RB (2001) TGF-β increases retinal endothelial cell permeability by increasing MMP-9: possible role of glial cells in endothelial barrier function. Invest Ophthalmol Vis Sci 42:853–859PubMed

35.

Das A, Fanslow W, Cerretti D, Warren E, Talarico N, McGuire P (2003) Angiopoietin/Tek interactions regulate MMP-9 expression and retinal neovascularization. Lab Invest 83:1637–1645PubMedCrossRef

36.

Giebel SJ, Menicucci G, McGuire PG, Das A (2005) Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood–retinal barrier. Lab Invest 85:597–607PubMedCrossRef

37.

Taraboletti G, D’Ascenzo S, Borsotti P, Giavazzi R, Pavan A, Dolo V (2002) Shedding of the matrix metalloproteinases MMP-2, MMP-9, and MT1-MMP as membrane vesicle-associated components by endothelial cells. Am J Pathol 160:673–680PubMed

38.

Das A, McGuire PG, Eriqat C, Ober RR, De Juan E Jr, Williams GA et al (1999) Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 40:809–813PubMed

39.

Noda K, Ishida S, Inoue M, Obata K, Oguchi Y, Okada Y et al (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44:2163–2170PubMedCrossRef

40.

Abu El-Asrar AM, Dralands L, Veckeneer M, Geboes K, Missotten L, Van Aelst I et al (1998) Gelatinase B in proliferative vitreoretinal disorders. Am J Ophthalmol 125:844–851PubMedCrossRef

41.

Johnson C, Sung HJ, Lessner SM, Fini ME, Galis ZS (2004) Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res 94:262–268PubMedCrossRef

42.

Das A, McLamore A, Song W, McGuire P (1999) Retinal neovascularization is suppressed with a MMP inhibitor. Arch Ophthalmol 117:498–503PubMed

Title: Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders
Authors: Ahmed M. Abu El-Asrar
Philippe E. Van den Steen
Saleh A. Al-Amro
Luc Missotten
Ghislain Opdenakker
Karel Geboes
Publication date: 01-02-2007
Publisher: Kluwer Academic Publishers
Published in: International Ophthalmology / Issue 1/2007
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-007-9053-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2007

A case of mycotic endophthalmitis after triamcinolone acetonide-assisted pars plana vitrectomy

Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia

Long-term results of adjunctive use of mitomycin C in external dacryocystorhinostomy

Analysis of the visual and refractive outcome following laser in situ keratomileusis (LASIK) retreatment over a four-year follow-up period

Acanthamoeba keratitis related to orthokeratology

Late dislocation of an anterior chamber intraocular lens into the vitreous